Discovery of Novel Glutaminase (GLS1) and Histone Deacetylase (HDAC) Dual Inhibitors as a Promising Strategy for Cancer Therapy
- J Med Chem. 2026 Oct 8;69(19):22138-22161. doi: 10.1021/acs.jmedchem.6c01288.
- 1. Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing211198, P. R. China.
- 2. Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing211198, P. R. China.
- 3. Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing210006, P. R. China.
Glutaminase 1 (GLS1) and histone deacetylases (HDACs) are important targets involved in Cancer metabolism and epigenetic regulation, respectively. Herein, we report the design, synthesis, and biological evaluation of first-in-class GLS1/HDAC dual inhibitors as a single-molecule strategy for Cancer therapy. Through systematic structure-activity relationship studies and biochemical profiling, compound 58 was identified as a promising dual inhibitor with moderate GLS1 inhibition and potent HDAC activity, particularly against HDAC6. Compound 58 exhibited strong antiproliferative activity in multiple Cancer cell lines and modulated GLS1-associated glutamine metabolism and HDAC-related acetylation markers in cells. In a CT26 tumor-bearing mouse model, compound 58 achieved a tumor growth inhibition (TGI) rate of 91.10% without obvious systemic toxicity. Overall, this study supports GLS1/HDAC dual inhibition as a promising Anticancer strategy and provides compound 58 as a valuable lead for further optimization.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer